Atezolizumab as first-line therapy (1L) for advanced PD-L1-selected NSCLC patients: updated ORR, PFS, OS and exploratory biomarker results from the BIRCH study
Eberhardt W, Garassino M, Rizvi N, Besse B, Jänne P, Peters S, Toh C, Kurata T, Costa E, Koczywas M, Font E, Chaft J, Qiu J, Kowanetz M, Zou W, Coleman S, Mocci S, Sandler A, Gettinger S, Johnson M. Atezolizumab as first-line therapy (1L) for advanced PD-L1-selected NSCLC patients: updated ORR, PFS, OS and exploratory biomarker results from the BIRCH study. Pneumologie 2017, 71: s1-s125. DOI: 10.1055/s-0037-1598277.Peer-Reviewed Original ResearchOA03.02 Atezolizumab as 1L Therapy for Advanced NSCLC in PD-L1–Selected Patients: Updated ORR, PFS and OS Data from the BIRCH Study
Garassino M, Rizvi N, Besse B, Jänne P, Christoph D, Peters S, Toh C, Kurata T, Costa E, Koczywas M, Felip E, Chaft J, Qiu J, Kowanetz M, Coleman S, Mocci S, Sandler A, Gettinger S, Johnson M. OA03.02 Atezolizumab as 1L Therapy for Advanced NSCLC in PD-L1–Selected Patients: Updated ORR, PFS and OS Data from the BIRCH Study. Journal Of Thoracic Oncology 2017, 12: s251-s252. DOI: 10.1016/j.jtho.2016.11.239.Peer-Reviewed Original Research
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply